Khan Nabeel, Sundararajan Ramaswamy, Mahmud Nadim
Department of Gastroenterology, Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA, USA.
Division of Gastroenterology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
Crohns Colitis 360. 2025 Jul 9;7(3):otaf037. doi: 10.1093/crocol/otaf037. eCollection 2025 Jul.
There is limited real-world data on the long-term effectiveness and safety of tofacitinib among ulcerative colitis (UC) patients, especially among the elderly. Our aim was to evaluate these parameters among UC patients who had remained on the drug 1 year after initiation of therapy.
We conducted a retrospective cohort study, utilizing the US National Veterans Affairs Healthcare System, including patients with UC who received tofacitinib. The primary endpoint was effectiveness at the end of follow-up. The secondary endpoint was to evaluate if the effectiveness was different among the elderly compared to the young. Adverse events associated with the drug, like herpes zoster, major adverse cardiovascular events, deep vein thrombosis, as well as infections and malignancy during follow-up were also assessed.
In total, 159 patients were included in the study, among whom 51 were in the elderly group and 108 were in the younger group. The median duration of follow-up was 1.47 years (range, 0.01-5.49 years). Effectiveness of tofacitinib among the cohort was 56.60% (90 out of 159 patients). The effectiveness was higher in the elderly ( = .005).
In this nationwide cohort of UC patients, the effectiveness of tofacitinib was seen in a little over half the number of patients, with higher rates of effectiveness reported among the elderly. No new safety concerns were raised, especially among the elderly.
关于托法替布在溃疡性结肠炎（UC）患者，尤其是老年患者中的长期有效性和安全性，现实世界的数据有限。我们的目的是评估在开始治疗1年后仍继续使用该药物的UC患者中的这些参数。
我们利用美国国家退伍军人事务医疗保健系统进行了一项回顾性队列研究，纳入接受托法替布治疗的UC患者。主要终点是随访结束时的有效性。次要终点是评估老年人与年轻人相比有效性是否存在差异。还评估了与该药物相关的不良事件，如带状疱疹、主要不良心血管事件、深静脉血栓形成，以及随访期间的感染和恶性肿瘤。
该研究共纳入159例患者，其中老年组51例，年轻组108例。中位随访时间为1.47年（范围为0.01 - 5.49年）。托法替布在该队列中的有效性为56.60%（159例患者中的90例）。老年人的有效性更高（P = 0.005）。
在这个全国性的UC患者队列中，略超过半数的患者显示出托法替布的有效性，老年人中的有效性率更高。未出现新的安全问题，尤其是在老年人中。
